Agenus - mark

At Agenus, we believe the best path for treating disease is through activating our own body’s natural mechanisms.

That’s why for 20 years, we’ve focused on building technologies and a product pipeline aimed at treating cancer and infectious disease by helping the body’s immune system target diseased cells with precision.

  • 09 Sep 2015

    Agenus Inc. Completes $115 Million Non-Dilutive Royalty Transaction with Oberland Capital
    Read More


  • 08 Sep 2015

    Agenus to Present at the Rodman & Renshaw 17th Annual Global Investment Conference
    Read More


  • 24 Jul 2015

    GSK's Malaria Vaccine Containing Agenus' QS-21 Stimulon® Receives Positive Opinion from European Regulators for Prevention of Malaria in Young Children in Sub-Saharan Africa
    Read More


  • 23 Jul 2015

    Agenus Reports Second Quarter 2015 Financial Results
    Read More


  • 20 Jul 2015

    Agenus Acquires Novel Antibodies to Immuno-oncology Target CEACAM1
    Read More


  • 16 Jul 2015

    Agenus to Report Second Quarter 2015 Financial Results on July 23, 2015; Conference Call to Follow
    Read More


  • 22 Jun 2015

    Agenus to Webcast Annual Meeting of Stockholders
    Read More